BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 29052761)

  • 1. Does surgical delay for radical prostatectomy affect biochemical recurrence? A retrospective analysis from a Canadian cohort.
    Zanaty M; Alnazari M; Ajib K; Lawson K; Azizi M; Rajih E; Alenizi A; Hueber PA; Tolmier C; Meskawi M; Saad F; Pompe RS; Karakiewicz PI; El-Hakim A; Zorn KC
    World J Urol; 2018 Jan; 36(1):1-6. PubMed ID: 29052761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.
    Abdollah F; Sood A; Sammon JD; Hsu L; Beyer B; Moschini M; Gandaglia G; Rogers CG; Haese A; Montorsi F; Graefen M; Briganti A; Menon M
    Eur Urol; 2015 Sep; 68(3):497-505. PubMed ID: 26119559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
    Kumar A; Samavedi S; Mouraviev V; Bates AS; Coelho RF; Rocco B; Patel VR
    J Robot Surg; 2017 Mar; 11(1):37-45. PubMed ID: 27245233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncologic outcomes at 10 years following robotic radical prostatectomy.
    Diaz M; Peabody JO; Kapoor V; Sammon J; Rogers CG; Stricker H; Lane Z; Gupta N; Bhandari M; Menon M
    Eur Urol; 2015 Jun; 67(6):1168-1176. PubMed ID: 24996687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detectable Prostate-specific antigen value between 0.01 and 0.1 ng/ml following robotic-assisted radical prostatectomy (RARP): does it correlate with future biochemical recurrence?
    Zakaria AS; Schwartz RN; Hodhod A; Couture F; Tholomier C; Shahine H; Negrean C; Nguyen DD; Zanaty M; Stolzenbach F; Karakiewicz PI; El-Hakim A; Zorn KC
    World J Urol; 2021 Jun; 39(6):1853-1860. PubMed ID: 32696130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of the Biochemical Recurrence risk between Radical Prostatectomy and Brachytherapy in the treatment of low- and intermediate-risk prostate cancer].
    Martínez PF; Belisle DF; Cristallo C; Tobía I; Damia O; Villamil W; Giudice CR
    Arch Esp Urol; 2015 Oct; 68(8):655-60. PubMed ID: 26437328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does surgical delay for radical prostatectomy affect patient pathological outcome? A retrospective analysis from a Canadian cohort.
    Zanaty M; Alnazari M; Lawson K; Azizi M; Rajih E; Alenizi A; Hueber PA; Meskawi M; Lebacle C; Lebeau T; Benayoun S; Karakiewicz PI; El-Hakim A; Zorn KC
    Can Urol Assoc J; 2017 Aug; 11(8):265-269. PubMed ID: 28798829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for biochemical recurrence after robotic assisted radical prostatectomy: a single surgeon experience.
    Tanimoto R; Fashola Y; Scotland KB; Calvaresi AE; Gomella LG; Trabulsi EJ; Lallas CD
    BMC Urol; 2015 Apr; 15():27. PubMed ID: 25879548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positive surgical margins and biochemical recurrence following minimally-invasive radical prostatectomy - An analysis of outcomes from a UK tertiary referral centre.
    Sachdeva A; Veeratterapillay R; Voysey A; Kelly K; Johnson MI; Aning J; Soomro NA
    BMC Urol; 2017 Oct; 17(1):91. PubMed ID: 28969608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy.
    Narita S; Mitsuzuka K; Tsuchiya N; Koie T; Kawamura S; Ohyama C; Tochigi T; Yamaguchi T; Arai Y; Habuchi T;
    Int J Urol; 2015 Nov; 22(11):1029-35. PubMed ID: 26290306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of surgical wait times during summer months on the oncological outcomes following robotic-assisted radical prostatectomy: 10 years' experience from a large Canadian academic center.
    Zakaria AS; Couture F; Nguyen DD; Tholomier C; Shahine H; Stolzenbach F; Meskawi M; Karakiewicz PI; El-Hakim A; Zorn KC
    World J Urol; 2021 Aug; 39(8):2913-2919. PubMed ID: 33106941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness of robot-assisted versus open radical prostatectomy cancer control.
    Hu JC; Gandaglia G; Karakiewicz PI; Nguyen PL; Trinh QD; Shih YC; Abdollah F; Chamie K; Wright JL; Ganz PA; Sun M
    Eur Urol; 2014 Oct; 66(4):666-72. PubMed ID: 24602934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of selective nerve sparing in high risk prostate cancer during robot-assisted radical prostatectomy.
    Kumar A; Samavedi S; Bates AS; Mouraviev V; Coelho RF; Rocco B; Patel VR
    J Robot Surg; 2017 Jun; 11(2):129-138. PubMed ID: 27435701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Does the delay from prostate biopsy to radical prostatectomy influence the risk of biochemical recurrence?].
    Meunier ME; Neuzillet Y; Radulescu C; Cherbonnier C; Hervé JM; Rouanne M; Molinié V; Lebret T
    Prog Urol; 2018 Sep; 28(10):475-481. PubMed ID: 29907495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long term biochemical recurrence free survival after radical prostatectomy for cancer: comparative analysis according to surgical approach and clinicopathological stage].
    Rizk J; Ouzzane A; Flamand V; Fantoni JC; Puech P; Leroy X; Villers A
    Prog Urol; 2015 Mar; 25(3):157-68. PubMed ID: 25614075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Learning curve of minimally invasive radical prostatectomy: Comprehensive evaluation and cumulative summation analysis of oncological outcomes.
    Sivaraman A; Sanchez-Salas R; Prapotnich D; Yu K; Olivier F; Secin FP; Barret E; Galiano M; Rozet F; Cathelineau X
    Urol Oncol; 2017 Apr; 35(4):149.e1-149.e6. PubMed ID: 28117215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Favorable risk factors in patients with positive surgical margin after robot-assisted radical prostatectomy.
    Ha YS; Kang DI; Kim JH; Joung JY; Yu J; Parihar JS; Salmasi AH; Horie S; Kim WJ; Yi Kim I
    Can J Urol; 2014 Jun; 21(3):7290-7. PubMed ID: 24978359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrasensitive prostate-specific antigen level as a predictor of biochemical progression after robot-assisted radical prostatectomy: Towards risk adapted follow-up.
    Grivas N; de Bruin D; Barwari K; van Muilekom E; Tillier C; van Leeuwen PJ; Wit E; Kroese W; van der Poel H
    J Clin Lab Anal; 2019 Feb; 33(2):e22693. PubMed ID: 30365194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of statin use on clinicopathological characteristics of localized prostate cancer and outcomes obtained after radical prostatectomy: a single center study.
    Cattarino S; Seisen T; Drouin SJ; Renard-Penna R; Leon P; Comperat E; Mozer P; Cussenot O; Rouprêt M
    Can J Urol; 2015 Apr; 22(2):7703-8. PubMed ID: 25891333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.